{
    "root": "3493a02e-c314-3f04-e063-6394a90a2621",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250507",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ],
    "indications": {
        "text": "rosuvastatin tablets indicated : reduce risk stroke , myocardial infarction , arterial revascularization procedures adults without established coronary heart disease increased risk cardiovascular ( cv ) disease based age , hscrp \u22652 mg/l , least one additional cv risk factor . adjunct diet : reduce ldl-c adults primary hyperlipidemia . reduce low-density lipoprotein cholesterol ( ldl-c ) slow progression atherosclerosis adults . reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "atherosclerosis (DOID:1936)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1936"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 , 5.1 , 8.6 ) full prescribing information rosuvastatin tablets modifications due . ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "rosuvastatin tablets , usp supplied : strength supplied ndc tablet description 5 mg bottles 90 child-resistant closure 68071-3844-9 pink colored , film-coated , circular tablets debossed \u201c g \u201d one side \u201c c \u201d side . storage store controlled room temperature , 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "rosuvastatin tablets contraindicated following conditions : acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity rosuvastatin excipients rosuvastatin tablets . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin tablets [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated:\n                  \n                     To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP \u22652 mg/L, and at least one additional CV risk factor.\n                     As an adjunct to diet to:\n                     Reduce LDL-C in adults with primary hyperlipidemia.\n                     Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.\n                     Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n                     Primary dysbetalipoproteinemia.\n                     Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH : Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 , 5.1 , 8.6 ) See full prescribing information for rosuvastatin tablets dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions_original": "Rosuvastatin Tablets, USP are supplied as:\n                  \n                     \n                        \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 How Supplied\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              5 mg\n                           \n                           \n                              Bottles of 90 with child-resistant closure\n                           \n                           \n                              68071-3844-9\n                           \n                           \n                              Pink colored, film-coated, circular tablets debossed with \u201cG\u201d on one side and \u201cC\u201d on the other side.\n                           \n                        \n                        \n                           \n                              \n                           \n                           \n                           \n                           \n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Rosuvastatin tablets are contraindicated in the following conditions:\n                  \n                     \n                        Acute liver failure or decompensated cirrhosis\n  \n    [see Warnings and Precautions (\n                           \n                              5.3)].\n  \n    \n                        \n                     \n                     \n                        Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets\n  \n    [see Adverse Reactions (\n                           \n                              6.1)]\n  \n    .",
    "drug": [
        {
            "name": "Rosuvastatin Calcium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ]
}